Why Editas Medicine Stock Sank Today
1 minuto de lectura
What happenedShares of Editas Medicine (NASDAQ: EDIT) sank 11.4% as of the market close on Wednesday. The big decline came after AbbVie (NYSE: ABBV) announced a partnership with privately held Caribou Biosciences to develop chimeric antigen receptor T cell (CAR-T) therapies.Read MoreMarketsMarkets Feed
Descubre más desde Espacioteca
Suscríbete y recibe las últimas entradas en tu correo electrónico.
